| 38.8878 -0.412 (-1.05%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 46.61 | 1-year : | 54.44 |
| Resists | First : | 39.9 | Second : | 46.61 |
| Pivot price | 38.68  |
|||
| Supports | First : | 38.51 |
Second : | 37.65 |
| MAs | MA(5) : | 39.28 |
MA(20) : | 38.73 |
| MA(100) : | 35.42 |
MA(250) : | 32.71 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 77.2 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 39.9 | Low : | 25.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ FTXH ] has closed below upper band by 40.6%. Bollinger Bands are 1.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.11 - 39.35 | 39.35 - 39.52 |
| Low: | 37.93 - 38.25 | 38.25 - 38.48 |
| Close: | 38.47 - 38.94 | 38.94 - 39.28 |
The First Trust Nasdaq Pharmaceuticals ETF (FTXH) operates as an exchange-traded fund. Its primary aim is to mirror the financial performance—both capital appreciation and income generation—of the Nasdaq US Smart Pharmaceuticals Index, prior to any fund-specific fees and expenses. To achieve this, the ETF endeavors to precisely replicate the constituents and their proportionate allocations within that index, striving for a performance correlation of at least 95%.
Thu, 30 Jul 2026
Should You Invest in the First Trust NASDAQ Pharmaceuticals ETF (FTXH)? - NewsBreak: Local News & Alerts
Wed, 29 Jul 2026
Top 10 ETF Creations and Redemptions: Latest Flows and Trends - news.ssbcrack.com
Tue, 28 Jul 2026
FTXH ETF Profile: Dividends, Returns (BOATS:FTXH) - TradingView
Thu, 16 Oct 2025
ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook - TradingView
Thu, 08 Aug 2024
LLYX Stock Fund Price and Chart — AMEX:LLYX - TradingView
Wed, 17 Apr 2024
The 5 Best Pharmaceutical ETFs of 2023 - ETF.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management - Global
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|